T he syndrome of resistance to thyroid hormone (RTH) is an inherited autosomal dominant human disease (1) . It is most commonly caused by point mutations in the THRB gene that encodes TR␤, 1 of 2 thyroid hormone (TH) receptors (TRs) in humans (2, 3) . TRs are ligand-gated transcription factors (4) , and most RTH mutations affect the C-terminal ligand-binding domain and reduce TR␤ affinity for hormone [triiodothyronine (T 3 )]. Patients frequently display defects in the hypothalamic-pituitary-thyroid (H-P-T) axis, resulting in elevated circulating TH and goiter, along with other symptoms. Interestingly, there appear to be 2 distinct forms of the disease; generalized resistance (GRTH) affects all tissues, whereas patients with isolated central resistance (CRTH, or pituitary resistance) exhibit specific defects in feedback inhibition of TH production with normal peripheral responses (2, 5) . However, there have been doubts that GRTH and CRTH are clinically-distinct entities (6, 7) . Investigators have often proposed that the 2 forms of RTH represent part of the same continuum of variable symptoms (8) and have pointed out that there is no consistent functional difference between GRTH and CRTH mutations (9) . In this issue of PNAS, Wondisford and colleagues (10) report a mouse model for CRTH and discover a startlingly simple explanation for the phenotype: hormone binding is specifically uncoupled from transcriptional inhibition, leaving transcriptional activation intact.
RTH is consistently associated with elevated circulating levels of TH and thyroid-stimulating hormone (TSH), which triggers TH release in the thyroid gland (Fig. 1A) . Usually, THs repress the genes that encode TSH-releasing hormone (TRH) in the hypothalamus, which triggers TSH release, and both subunits of TSH in the pituitary, thereby inhibiting their own synthesis and maintaining hormone levels within set concentration ranges. The system fails in RTH; TR␤ is mutated and TH cannot repress TRH and TSH transcription (Fig. 1B) .
What are the consequences of elevated TH? In normal individuals, excess TH causes thyrotoxicosis, characterized by tachycardia, elevated metabolic rate, muscle and bone catabolism, and other effects (4). Most of these symptoms are absent in GRTH and patients often appear normal because elevated TH compensates for reduced affinity of the mutant TR␤ for T 3 . In other cases, patients with more severe mutations display symptoms associated with TH deficit (4), mental retardation, deafness, and delayed bone growth and maturation. One exception is that GRTH patients can display tachycardia, a classic symptom of hyperthyroidism. This exception is because heart rate is predominantly controlled by the TR␣ isoform, which is unaffected by RTH mutations and hyperstimulated by excess TH (4) .
What of CRTH? The first description of this disease emerged in 1975 (11) , and there have been many subsequent diagnoses (8) . Patients generally display hyperthyroid symptoms along with elevated TSH (which should be suppressed by high TH). However, RTH symptoms are highly variable (7, 8) ; members of the same kindred often exhibit different features and identical mutations have been detected in different families that have been classified as GRTH or CRTH. Thus, the separate existence of CRTH is controversial, and investigators have often suggested that GRTH and CRTH represent opposite poles of the same continuum of disease symptoms (6, 7). Further, detailed laboratory characterization of effects of GRTH and PRTH mutations on TR function have failed to reveal consistent features that distinguish the 2 forms of the disease (9) . Interestingly, targeting of TR␤ GRTH mutants to pituitary thyrotropes in transgenic mice does reproduce CRTH symptoms, confirming that a specific central defect can lead to phenotypes that resemble human disease (12, 13) . However, debates about the nature of CRTH, and even its very existence, have remained far from resolved. This is a wonderful era for the biologist; we are no longer completely reliant on natural mutations to understand gene function in mammals. Instead, the ability to delete and recombine specific DNA sequences in the mouse germ line lends the researcher an unprecedented armory of weapons to dissect the normal role of specific gene products. Wondisford and colleagues (10) use a rapier; they introduce a CRTH mutation (R429Q) into the TR␤ gene and examine its effects on TH signaling in the mouse.
The R429Q mutant mouse recapitulates CRTH. Like previous knockin mouse models of GRTH (14) there are defects in the H-P-T axis; serum TH levels were 3-4 higher than wild-type littermates and heterozygotes displayed 2-fold increases. Moreover, serum TSH levels and TSH transcript levels were high and not suppressed efficiently by T 3 . However, there was normal activation of several positively-regulated genes, including growth hormone in the pituitary, deiodinase 1 and thrsp in liver and Myh6 (␣-MHC) in heart, and weight loss, a symptom of hyperthyroidism. More surprisingly, negative regulation was disrupted globally, not just in the H-P-T axis. T 3 inhibition of peripheral genes, gsta in liver and myh7 (␤-MHC) in heart, was severely impaired. The R429Q mutation is a less frequent example of an RTH mutant that does not reduce TR affinity for T 3 . Thus, the mutation uncouples hormone binding from transcriptional repression, likely explaining the apparent specific defect on transcriptional repression in the H-P-T axis. Wondisford and colleagues (10) propose that this is the key feature that distinguishes CRTH mutations from GRTH mutations (Fig. 1C) .
Like all good science, the study raises new issues. Why does the R429Q mutation specifically block repressive effects? It is very difficult to answer this question; basic mechanisms of transcriptional repression remain poorly understood (4, 15) . It is known that TR␤R429Q exhibits a selective defect in TR-TR homodimerization but not TR-retinoid X receptor heterodimer formation. However, several different RTH mutations exhibit the same defect in homodimer formation, yet only some lead to CRTH (9) . The R429Q mutation also blocks TR interactions with the corepressor N-CoR (9) , and this phenotype is shared with another severe CRTH mutation (MKAR) (16) . However, a recent study (17) revealed that TR/N-CoR interactions are largely dispensable for transcriptional repression in liver, suggesting that blockade of N-CoR interactions alone cannot explain global defects in transcriptional repression observed in CRTH. Finally, R429 lies in a cluster of charged residues that are crucial for TR stability, perhaps raising the possibility that the mutation could alter TR dynamics and indirectly affect TR conformation at distant functional sites required for transcriptional repression (18) .
Although studies of RTH mutants have led to better understanding of the disease, there has also been at least 1 spin-off in pharmaceutical development (15) . The observation that TR␣ activation leads to tachycardia helped to initiate the development of TR␤-selective drugs to reduce cholesterol and lower weight without harmful effects on heart. Could improved understanding of the R429Q mutation lead to new pharmaceuticals that could separate T 3 -dependent activation from repression? We will have to wait and see.
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